Inspire Medical Systems (INSP) Inspire V device could be less utilized because of Medicare reimbursement uncertainty, RBC Capital Markets said in a note Tuesday.

A coding error at the Centers for Medicare & Medicaid Services has created a "physician disincentive," RBC said, as doctors will be paid less to perform Insipre V procedures.

"We are downgrading INSP following our Expert checks suggesting

Inspire V coding headwinds are likely to persist," RBC said, lowering its 2026 revenue estimate to $985.3 million from $1.01 billion.

RBC cut its rating on the stock to sector perform from outperform and reduced its price target to $90 from $175.

r

Price: 80.42, Change: -0.91, Percent Change: -1.12